SCHEMBL11972062

SCHEMBL11972062

Brc1ccc(SC2CCCC2)nc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 2/20 0.50
CRBN Q96SW2 2/20 0.50
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
ALDH1A1 P00352 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.36
VCP P55072 7/20 0.36
MAOA P21397 3/20 0.33
MAOB P27338 3/20 0.33
PLAU P00749 1/20 0.31
ADRA2A P08913 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
GBA1 P04062 1/20 0.31
OPRM1 P35372 1/20 0.30
OPRL1 P41146 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL640212 0.92 DDB1 (0.53) DDB1CRBNPDGFRBPDGFRAALDH1A1
SCHEMBL851197 0.78 PDGFRB (0.39) DDB1CRBNPDGFRBPDGFRAALDH1A1
SCHEMBL10834649 0.78 MAOA (0.47) DDB1CRBNPDGFRBPDGFRAALDH1A1
SCHEMBL11546966 0.76 PDGFRB (0.38) DDB1CRBNPDGFRBPDGFRAALDH1A1
SCHEMBL19641578 0.74 HRH3 (0.36) DDB1CRBNPDGFRBPDGFRAVCP
SCHEMBL851094 0.74 PDGFRB (0.36) DDB1CRBNPDGFRBPDGFRAALDH1A1
SCHEMBL508328 0.73 LOXL2 (0.37) PDGFRBPDGFRAALDH1A1SMN1; SMN2VCP
SCHEMBL11731794 0.71 ALDH1A1 (0.45) DDB1CRBNALDH1A1NPC1RAB9A
SCHEMBL21495203 0.71 KDM4E (0.41) DDB1CRBNALDH1A1NPC1RAB9A
SCHEMBL11433619 0.70 KDM4E (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340506-B2 Acetamide derivatives as glucokinase activators, their process and medicinal applications ADVINUS THERAPEUTICS LIMITED (IN) 2016-05-17 US disclosed
US-9340506-B2 Acetamide derivatives as glucokinase activators, their process and medicinal applications ADVINUS THERAPEUTICS LIMITED (IN) 2016-05-17 US disclosed
US-9340506-B2 Acetamide derivatives as glucokinase activators, their process and medicinal applications ADVINUS THERAPEUTICS LIMITED (IN) 2016-05-17 US disclosed
US-20120214735-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS ADVINUS THERAPEUTICS LIMITED (IN) 2012-08-23 US disclosed
US-20120214735-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS ADVINUS THERAPEUTICS LIMITED (IN) 2012-08-23 US disclosed
US-20120214735-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS ADVINUS THERAPEUTICS LIMITED (IN) 2012-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214735-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS GCK, GCKR, ALDOA DDB1 4678/4885CRBN 4829/4885PDGFRB 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.